Skip to main content
. 2011 Nov 16;16(12):1762–1770. doi: 10.1634/theoncologist.2011-0287

Table 2.

Adjuvant trial monotherapy arms analysis (median follow-up, 73 months)

graphic file with name onc01211-0936-t02.jpg

aITT analyses ignored selective crossover. Censored analyses censored follow-up/event times at the date of selective crossover in 632 women who crossed over to letrozole or another aromatase inhibitor after the tamoxifen arms were unblinded.

bAdjusted by randomization option and use of chemotherapy.

Abbreviations: CI, confidence interval; DFS, disease-free survival; ITT, intent to treat.